Global Bronchiectasis Treatment Market - 2022-2029

Global Bronchiectasis Treatment Market - 2022-2029

Market Overview

Bronchiectasis Treatment Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 6.0% during the forecast period (2022-2029).

Bronchiectasis is a condition affecting the airways in the lungs that causes cough, increased mucus production, and recurrent lung infections. The symptoms are caused by abnormal widening of the lung’s airways, also known as bronchi. The cells lining the airways become inflamed and swollen. These damaged airways can no longer effectively clear mucus and bacteria from the lung. This can lead to flare-ups of cough, mucus production, and shortness of breath. Bronchiectasis can further be diagnosed through chest X-ray, blood tests, computerized tomography (CT) scan, and lung function tests such as bronchoscopy and genetic blood tests.

Market Dynamics

The global bronchiectasis treatment market is growing due to several factors, such as the rising prevalence of respiratory diseases, the increasing geriatric population, and the ease of availability of low-cost drugs.

The rising prevalence of pulmonary diseases is expected to drive market growth.

According to the WHO, respiratory diseases impose an immense worldwide health burden. For instance, according to the World Bank population projections and Global Burden of Disease data for COPD from 39 countries in Europe in 2020, it is estimated that there were 36,580,965 Europeans with COPD. In 2050, it is projected that 49,453,852 people will have COPD (prevalence=9.3%), accounting for a 35.2% relative increase in patients and a 39.6% increase in prevalence. Moreover, According to Global Initiative for Asthma 2022 report, Asthma affects an estimated 300 million individuals worldwide. Also, according to WHO, in 2020, an estimated 10 million people fell ill with tuberculosis (TB) worldwide. 5.6 million men, 3.3 million women and 1.1 million children10.4 million people developed tuberculosis (TB), and a total of 1.5 million people died from it. The most common lethal neoplasm in the world is lung cancer; for instance, according to the Global Cancer observatory, in 2020, there were around 2206,771 new lung cancer cases, and it has caused 1 796,144 deaths.

The lack of approved drugs hinders global bronchiectasis treatment market growth.

However, the lack of approved drugs for bronchiectasis, stringent regulatory policies, high costs involved in research and development under-diagnosis of bronchiectasis, and preference for substitute treatment options are some factors hampering the growth of the bronchiectasis treatment market over the forecast period. The treatment costs increase with the severity of the disease and some factors such as age, chronic Pseudomonas aeruginosa infection, exacerbations, and hospital admissions.

Industry Analysis

The global bronchiectasis treatment market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, and pipeline analysis.

Segment Analysis

The antibiotics segment is expected to dominate the bronchiectasis treatment market throughout the forecast period (2022-2029).

The antibiotics segment accounted for the highest market share in the bronchiectasis treatment market, owing to the rising prevalence of several respiratory disorders, which leads to an increase in demand for the treatment of the disease. For patients with moderate-to-severe symptoms, parenteral antibiotics, such as an aminoglycoside (gentamicin, tobramycin) and antipseudomonal synthetic penicillin, a third-generation cephalosporin, or a fluoroquinolone, may be indicated. Patients with bronchiectasis from Cystic Fibrosis (CF) are often infected with mucoid pseudomonas species, and, as such, tobramycin is often the drug of choice for acute exacerbation. Infection with Mycobacterium Avium Complex (MAC) provides special treatment challenges. To treat MAC in bronchiectasis, the American Thoracic Society recommends a 3- to 4-drug treatment regimen with clarithromycin, rifampin, ethambutol, and possibly streptomycin continued until the patient's culture results are negative for 1 year. The typical duration of therapy may be 18-24 months.

Geographical Analysis

The North American region holds the largest market share of the global bronchiectasis treatment market.

North America is dominating the global bronchiectasis treatment market, accounting for the largest market share in 2021, owing to the rising prevalence of respiratory diseases, increasing research and development activities for drug development, and technological advancements in the treatment of bronchiectasis. For instance, according to the American Cancer Society, estimates for lung cancer by the end of 2022 in the United States indicate that there will be about 236,740 new cases of lung cancer (117,910 in men and 118,830 in women) and about 130,180 deaths from lung cancer (68,820 in men and 61,360 in women). Furthermore, according to CDC, around 7,860 reported TB cases in the United States in 2021, and up to 13 million people in the United States are living with latent TB infection. Older age raises the risk of bronchiectasis; therefore, the growing geriatric population in North America is fueling its dominance over the global market; for instance, according to the Census Bureau's 2020 population estimates, more than 55 million Americans are age 65 or older.

Competitive Landscape

The bronchiectasis treatment market is highly competitive, with many major players and small vendors. Major global bronchiectasis treatment market players include Grifols SA, GlaxoSmithKline Plc, Sanofi, Boehringer-Ingelheim, Cadilapharma, Aradigm Corporation, Zambon S.p.A., Santhera Pharmaceuticals Holding AG, Bayer AG, Insmed Inc, Alitair Pharmaceuticals Inc, Polyphor Ltd, Kamada Ltd, among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the bronchiectasis treatment market globally. For instance, on 16 August 2022, GSK acquired Affinivax, Inc.

GlaxoSmithKline Plc.

Overview:

GSK is a global biopharma company dealing with prescription and nonprescription products. GSK was founded on 27 December 2000 and had headquarters in Brentford, United Kingdom. GSK has 45+ subsidiaries which create its global presence.

Product Portfolio:

GlaxoSmithKline Plc’s product portfolio for bronchiectasis treatment has TRELEGY Ellipta, Anoro Ellipta, Incruse Ellipta.

The global bronchiectasis treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.